Equibles does not estimate personal net worth.
Get an email with a short summary when Spero Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get SPRO alertsEsther Rajavelu is recorded as CFO, CEO and Board Member at Spero Therapeutics, Inc. (SPRO). The newest filing on record that lists Esther Rajavelu as CEO and Board Member at Spero Therapeutics, Inc. (SPRO) is dated April 27, 2026. The newest filing on record that lists Esther Rajavelu as CFO at Spero Therapeutics, Inc. (SPRO) is dated April 16, 2024. Spero Therapeutics, Inc. reported in an 8-K filed April 28, 2025 that Esther Rajavelu was appointed President and Chief Executive Officer, effective May 2, 2025. Spero Therapeutics, Inc. reported in an 8-K filed November 1, 2023 that Esther Rajavelu was appointed Chief Financial Officer and Chief Business Officer, effective October 30, 2023. The proxy statement of Spero Therapeutics, Inc. reports total compensation of $2,061,496 for Esther Rajavelu in fiscal 2025, including a base salary of $577,179. Disclosed compensation is on record for 3 fiscal years. Esther Rajavelu has spoken on 3 earnings calls and 1 other investor event across 1 company, most recently for Spero Therapeutics, Inc. on September 15, 2026. Spero Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Spero Therapeutics, Inc. includes Ankit Mahadevia, M.D. (Chairman), Frank E. Thomas (Chairman), Frank Thomas (Chairman) and 7 others.
“On April 28, 2025, Spero Therapeutics, Inc. (the "Company") announced that effective as of May 2, 2025 (the "Effective Date"), Esther Rajavelu will serve as the Company's President and Chief Executive Officer.”
“On October 30, 2023, the Board of Directors (the “Board”) of Spero Therapeutics, Inc. (the “Company”) appointed Esther Rajavelu as the Company’s Chief Financial Officer and Chief Business Officer.”
“It's great to be here and to be having the opportunity to present the Sparrow Therapeutics story to you all. Before we get going, the obligatory forward-looking statements.”
“Good afternoon, everyone, and thank you for joining us on our second quarter earnings and business update call. I will begin with key highlights from the quarter, outline our strategy and priorities going forward, and then review our financial results.”
“Good afternoon, everyone, and thank you for joining our second quarter 2025 earnings and business update call.”
“I'll begin with our cash guidance first and then summarize our GAAP financials. Spero ended the second quarter with $63.5 million in cash and cash equivalents.”
Source not stated
Start not stated–present
Last confirmed April 16, 2024
Start not stated–present
Last confirmed April 27, 2026
Start not stated–present
Last confirmed April 27, 2026
Biotechnology · Healthcare
CFO, CEO, Board Member
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Spero Therapeutics, Inc. (SPRO) | President and Chief Executive Officer, Chief Financial Officer, Chief Business Officer and Treasurer | $577,179 | $2,061,496 |
| 2024 | Spero Therapeutics, Inc. (SPRO) | President and Chief Executive Officer, Chief Financial Officer, Chief Business Officer and Treasurer | $483,313 | $856,479 |
| 2023 | Spero Therapeutics, Inc. (SPRO) | Interim President and Chief Executive Officer, Chief Financial Officer, Chief Business Officer and Treasurer | $73,769 | $458,054 |
